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Summary  
 
We performed a subgroup analysis of the phase III UK NCRI R-
CHOP14 versus R-CHOP21 trial to evaluate the outcomes for patients 
meeting the WHO 2008 criteria for primary mediastinal B-cell 
lymphoma (PMBL). Fifty patients meeting the criteria were identified 
from the trial database. At a median follow-up of 7.2 yrs the 5-yr PFS 
and OS were 79.8% and 83.8% respectively. An exploratory analysis 
raised the possibility of a better outcome in those who received R-
CHOP14 and time intensification may still, in the rituximab era, merit 
testing in a randomised trial in this subgroup of patients.  
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Introduction:  
Primary Mediastinal B-cell Lymphoma (PMBL) is a distinct subtype 
of diffuse large B-cell lymphoma (DLBCL) arising from putative 
thymic B-cells in the mediastinum and comprises 2-4% of all non-
Hodgkin lymphomas (NHLs) (Gaulard et al, 2008). PMBL has unique 
clinicopathologic and genotypic features and is characterised by a 
bulky antero-superior mediastinal mass, which often directly invades 
local structures including lungs, pleura or pericardium, and is 
frequently associated with superior vena cava syndrome. In contrast to 
DLBCL, PMBL patients are typically younger (median age 35 years) 
and there is usually a female predominance. Spread to supraclavicular 
or cervical lymph nodes can occur but absence of other lymph node or 
bone marrow involvement is required to exclude DLBCL with 
secondary mediastinal involvement (Gaulard et al, 2008).  
Combination chemotherapy with rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisolone (R-CHOP) with or without 
consolidative radiotherapy (RT) is the most commonly used regimen 
in the first-line management of PMBL with reported 5-yr OS rates of 
79-89% (Savage et al, 2006; Rieger et al, 2011; Soumerai et al, 2014). 
However with the exception of the MInT trial (which evaluated 
patients with PMBL aged ≤60 years with an age-adjusted International 
Prognostic Index of 0-1) (Rieger et al, 2011); the evidence-base for R-
CHOP in PMBL comes from retrospective studies. 
Several studies in PMBL from the pre-rituximab era suggested a 
benefit for third-generation regimens such as etoposide/methotrexate, 
doxorubicin, cyclophosphamide, vincristine, prednisolone and 
bleomycin (V/MACOP-B) over CHOP (Lazzarino et al, 1993; Zinzani 
et al, 2002; Todeschini et al, 2004). These weekly regimens were 
intended to be dose-intensified, based on the Skipper model (Hryniuk 
et al, 1998) but they typically involved reduction of the total dose of 
anthracyclines which are the most effective class of lymphoma drugs 
(Hasenclever et al, 2001). These regimens were, however, time-
intensified with the cytotoxic drugs delivered over 11 weeks rather 
than the 15 weeks with 6 cycles of CHOP. Recently excellent results 
have been reported in a small single-arm prospective phase 2 study 
from National Cancer Institute (NCI) with the infusional regimen of 
dose-adjusted etoposide, doxorubicin, cyclophosphamide with 
vincristine, prednisolone plus rituximab (DA-EPOCH-R) (Dunleavy 
et al, 2013), but it is unclear whether these results are significantly 
better than can be achieved with R-CHOP. 
The aim of this subgroup analysis was to evaluate the outcomes for 
patients with PMBL treated with R-CHOP with or without RT within 
the randomised prospective UK NCRI R-CHOP 14 versus 21 trial. An 
exploratory analysis was also carried out on the impact of time-
intensification with the R-CHOP14 regimen. 
 
Methods:  
The phase III UK NCRI R-CHOP-14 versus 21 trial compared R-
CHOP given 2-weekly versus 3-weekly in previously untreated 
patients aged ≥18 years with bulky stage I-IV histologically proven 
DLBCL. A total of 1,080 patients from 119 centres across the United 
Kingdom were enrolled from 2005-2008 and randomised in a one-to-
one ratio to receive either 6 cycles of R-CHOP every 14 days (R-
CHOP-14) plus 2 cycles of rituximab or 8 cycles of R-CHOP every 21 
days (R-CHOP-21). We previously reported that R-CHOP-14 was not 
superior to R-CHOP-21 for OS, progression free survival (PFS), 
response rate or safety (Cunningham et al, 2013).  
Response following induction chemotherapy with R-CHOP was 
evaluated by a CT scan of the thorax, abdomen, and pelvis with or 
without neck. 18F-fluorodeoxyglucose-positron-emission-
tomography-CT (FDG-PET-CT) scans were not mandated by the trial 
protocol and therefore no FDG-PET-CT data were collected as part of 
the main study. Administration of consolidation RT on study was 
permitted at the discretion of the local investigator. 
Patients with PMBL were not excluded from enrollment and cases 
were identified by searching the trial database for patients with a 
“bulky” mediastinal mass at baseline (a minimum cut-off of 5cm 
diameter was used) who also fulfilled the World Health Organization 
(WHO) 2008 criteria for sites of involvement at presentation, that is 
absence of disease involvement outside of the thorax with or without 
cervical / supraclavicular lymph node involvement (Gaulard et al, 
2008). 
 
Statistical Analysis: 
The outcomes in this subgroup analysis are the same as in the overall 
study: the primary endpoint was OS and the secondary endpoints were 
PFS and response rate. PFS and OS were calculated from the date of 
randomisation, censored at the date last seen, and analysed using 
Kaplan-Meier and Cox regression models. End of treatment response 
was assessed according to the 1999 International Working Group 
(IWG) criteria (Cheson et al, 1999).  
 
Results:  
Fifty of 1,080 (4.6%) patients from the R-CHOP 14 versus 21 study 
database met the WHO 2008 clinical criteria. Baseline characteristics 
are demonstrated in Table I. The median age at diagnosis was 38.5 
years and 50.0% of patients were female.  All patients had stage I or II 
disease and the median mediastinal mass diameter was 11.1cm. 
Twenty-eight patients (56.0%) were treated with R-CHOP-21 and 22 
patients (44.0%) received R-CHOP-14.  On completion of R-CHOP 
chemotherapy response by CT was complete in 42.9% (n=21), partial 
in 49.0% (n=24), stable disease in 2.0% (n=1) and progressive disease 
in 6.1% (n=3). End of treatment response was not evaluable for 1 
patient. Radiotherapy was administered to 58.0% of patients (n=29).  
After a median follow-up of 7.2 years, the 5-year PFS was 79.8% 
(95% CI 68.6-91.0) and 5-year OS was 83.8% (95% CI 73.4-94.2) 
[Figure 1A and 1B]. Where disease progression occurred 9/10 events 
occurred within the first-year of follow-up. For the 9 patients who 
died in our cohort the causes of death were documented as 
progressive disease (n=7), cardiac-related (n=1) and in one case the 
cause of death was unknown. Eight out of ten progressions and 8/9 
deaths occurred in patients who received R-CHOP-21 [Figure 1C and 
1D]. The difference in OS between the two treatment arms 
approached statistical significance (p=0.06). Five out of ten 
progressions and 4/9 deaths occurred in patients who had received 
RT consolidation post-R-CHOP. 
 
Discussion: Our data confirms the efficacy of R-CHOP (with or 
without RT) in the management of PMBL and serves as a benchmark 
for future studies. This is, to our knowledge, the largest reported 
cohort of patients with PMBL treated with R-CHOP within a 
prospective trial. The additional strength of the data lies in the strict 
selection of patients according to the WHO 2008 clinical criteria for 
PMBL, the inclusion of all patients ≥18 years without an upper age 
limit, and the long duration of follow-up. Compared to the study of 
DA-EPOCH-R our patients were older (median age 38.5 years versus 
30 years) and our trial was multicentre, but despite this the 83.8% OS 
at 5 years is within the 95% confidence limits of the DA-EPOCH-R 
results (Dunleavy et al, 2013).  
More events occurred in patients treated with R-CHOP-21, and the 
difference in survival approached significance. However it should be 
noted that the number of patients in this subgroup analysis was small 
and this prevents a meaningful multivariate analysis to address the 
impact of any potentially confounding factors. As with other trial 
populations, it is also worth noting that very unwell patients 
presenting with PMBL were potentially excluded from study 
enrolment.  There is also no compelling biological reason why time-
intensification in the rituximab era should be more efficacious in this 
form of NHL than in other types of DLBCL, where time-
intensification has not impacted on outcome (Cunningham et al, 
2013). Nonetheless, together with the previous experience from the 
pre-rituximab era, this suggests that the impact of time-
intensification should be considered in future trials of this specific 
subtype of DLBCL. In our study RT was given at the clinician’s 
discretion, so it is not possible to draw conclusions about the value of 
this modality of therapy. The currently accruing IELSG-37 
randomised phase III trial (NCT 01599559), will address this 
important clinical question by evaluating the role of RT in FDG-
PET-CT negative patients following rituximab-containing induction 
chemotherapy, although it should be noted that a positive end of 
treatment PET scan, seen in approximately 40% of R-CHOP-
treated patients (Vassilakopoulos et al, 2016) is not indicative of 
impending disease progression (Dunleavy et al, 2013; Woessmann et 
al, 2013). 
In conclusion our analysis demonstrates that R-CHOP is an 
efficacious regimen in the management of PMBL. Although 
excellent results have been reported with the combination of DA-
EPOCH-R in PMBL, the benefit of such regimens over R-CHOP 
needs to be evaluated in prospective randomised trials and 
consideration should be given to further exploring the value of R-
CHOP14 in this group of patients. 
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Table I: Baseline Characteristics 
  
n=50 % 
Gender 
Male 
   Female 
 
25 
25 
 
50 
50 
Age (yrs) 
                                       Median (range) 
< 60 
≥
 
38.5 
46 
4 
 
 
22-78 
92 
8 
 
Stage  
I 
II 
 
18 
32 
 
36 
64 
Maximum diameter of mediastinal mass 
 
                                    Median (range)  
≤10cm 
>10 cm 
 
 
   11.1 
     15 
35 
 
 
 6-23 
  30 
  70 
B symptoms 
Absent 
Present 
 
24 
26 
 
48 
52 
Performance score                     
0 
1 
2 
 
29 
15 
6 
 
58 
30 
12 
IPI 
0 
1 
2 
3 
 
6 
36 
5 
3 
 
12 
72 
10 
6 
LDH 
Normal 
Raised 
 
8 
42 
 
16 
84 
 
 
 
 
 
 
 
 
 
Figure 1: Overall (A) and progression free survival (B) for all patients. 
Overall (C) and progression free survival (D) according to treatment 
arm. 
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